Eurofins Discovery
Eurofins Discovery is a global contract research organization providing drug discovery, safety pharmacology, and translational biology services—including specialized human bioassay development—to pharmaceutical and biotechnology companies.
- Company typePrivate
- Founded1987
- HeadquartersSt. Charles, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
What Eurofins Discovery does
Eurofins Discovery is a global contract research organization (CRO) that provides drug discovery and safety pharmacology services to pharmaceutical and biotechnology clients. Its core offerings span the preclinical pipeline, including comprehensive drug discovery services, safety assessment of drug candidates, and translational biology support, sold primarily through enterprise field sales on a project-based, quote-priced engagement model. The company is positioned as a horizontal services provider serving the broader pharma and biotech R&D segment rather than a vertical specialist in any single therapeutic area.
The company's underlying scientific stack centers on human-tissue-based assay development and safety pharmacology. In July 2022 Eurofins Discovery acquired DiscoveryBioMed, a CRO specializing in human bioassays developed from both diseased and normal human tissues, which added translational biology capabilities that are differentiated relative to standard preclinical CRO offerings. In April 2023 the company acquired Calixar for an undisclosed amount, further extending the service portfolio. Together, these acquisitions indicate a roll-up strategy focused on bolting on specialized scientific capabilities that complement the core drug discovery and safety pharmacology franchise.
Eurofins Discovery operates as a service line within Eurofins Scientific, a larger European testing and analytical services group, which provides global geographic reach and back-office scale. Revenue mechanics are professional services–driven, with project-based contracts and pricing not publicly disclosed. Headcount is reported in the 501–1,000 range, with primary operational sites documented at St. Charles (United States) and Birmingham, Alabama (inherited from DiscoveryBioMed). Customer logos are not publicly disclosed, and the segment approach is horizontal across pharmaceutical and biotechnology R&D buyers.
Eurofins Discovery firmographics
Firmographics- Name
- Eurofins Discovery
- Website
- https://eurofinsdiscoveryservices.com
- Company type
- Private
- Founded year
- 1987
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Eurofins Discovery is a global contract research organization providing drug discovery, safety pharmacology, and translational biology services—including specialized human bioassay development—to pharmaceutical and biotechnology companies.
- Ownership category
- akta.pro rank
Eurofins Discovery industry classification
Industry- Product category
- Drug Discovery & Contract Research Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)
- akta.pro secondary industries
- Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC), Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
Keywords
Where Eurofins Discovery is headquartered
LocationHeadquarters
- HQ city
- St. Charles
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Eurofins Discovery business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Contract Research Organization (CRO) Services: Eurofins Discovery generates revenue through providing drug discovery and safety pharmacology services as a contract research organization to pharmaceutical and biotechnology companies. Services include developing human bioassays, translational biology support, and comprehensive drug discovery solutions.
Go-to-market motion1 record
Distribution channels1 record
Eurofins Discovery product offering
Product offeringCore offering
Eurofins Discovery is a global contract research organization (CRO) providing drug discovery and safety pharmacology services to pharmaceutical and biotechnology companies. Its portfolio spans target identification through preclinical testing, including human bioassay development from diseased and normal human tissues, translational biology support, and safety assessment of drug candidates. The portfolio has been expanded through acquisitions such as DiscoveryBioMed (human tissue-based bioassays) and Calixar.
Product overview
Eurofins Discovery operates as a global provider of drug discovery services, consisting of core service offerings including safety pharmacology services and human bioassay development. The portfolio was expanded through the acquisition of DiscoveryBioMed, which specializes in human bioassays from diseased and normal human tissues, enhancing translational biology capabilities for R&D support.
Differentiator
Problem solved
Functional benefit
Products and services
- Drug Discovery Services
- Safety Pharmacology Services
- DiscoveryBioMed Human Bioassays
Companies that use Eurofins Discovery
Customer profileSegments1 record
Ideal customer profiles1 record
Eurofins Discovery technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Eurofins Discovery partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- DiscoveryBioMedcoreEurofins Discovery acquired DiscoveryBioMed, a CRO specializing in developing human bioassays from diseased and normal human tissues. The acquisition enhances Eurofins Discovery's portfolio of drug discovery services and supports translational biology for R&D. DiscoveryBioMed brings specialized capabilities in human tissue-based bioassays that complement Eurofins' existing drug discovery and safety pharmacology service offerings.
Scale indicators3 records
Recent moves2 records
Expansion highlights3 records
Eurofins Discovery competitors and assessment
Company assessmentEmerging players
- Sai Life Sciences: India-based CRO offering drug discovery, medicinal chemistry, DMPK, and safety services. An emerging competitor in mid-tier discovery outsourcing that overlaps with Eurofins Discovery's core offering.
Direct peers
- Evotec: Germany-based drug discovery CRO and integrated R&D platform offering target identification, hit discovery, and translational biology. Closely comparable to Eurofins Discovery's discovery-plus-translational positioning.
- WuXi AppTec: China-based contract research organization with extensive drug discovery and preclinical safety pharmacology offerings. Competes head-to-head with Eurofins Discovery for global pharma/biotech discovery outsourcing dollars.
- Labcorp Drug Development (formerly Covance): Large CRO providing drug discovery, preclinical, and clinical development services. Overlaps with Eurofins Discovery in preclinical and safety pharmacology work, serving the same pharma/biotech customer base.
- Charles River Laboratories: Global preclinical CRO offering discovery, safety pharmacology, and DMPK services to pharma and biotech. Directly comparable to Eurofins Discovery across the early-stage drug discovery workflow, with a much larger commercial footprint.
- Pharmaron: China-headquartered CRO offering drug discovery, DMPK, safety pharmacology, and translational services. Comparable scale and service mix to Eurofins Discovery, increasingly winning global discovery outsourcing mandates.
Broad incumbents
- Thermo Fisher Scientific (PPD): Through its PPD acquisition, Thermo Fisher offers integrated discovery, preclinical, and clinical CRO services. A broad incumbent that competes for the same large-pharma discovery outsourcing engagements.
- IQVIA: Global life sciences services giant with discovery, preclinical, and clinical CRO capabilities. Larger and broader than Eurofins Discovery, but competes in the same outsourced drug discovery market.
- Eurofins Scientific: Parent organization and global testing services conglomerate within which Eurofins Discovery operates. Provides shared infrastructure, client relationships, and capital that fundamentally shape the division's positioning.
Regional players
- Syneos Health: Clinical and preclinical CRO with strong North American presence serving pharma/biotech. Competes for overlapping preclinical and translational work, though its historical emphasis has been more clinical-stage than pure discovery.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Eurofins Discovery financial estimates
Financial estimateRevenue estimate
Valuation estimate
Eurofins Discovery leadership team
Management profileNumber of profiles
Eurofins Discovery subsidiaries and ownership
Company hierarchySubsidiaries1 record
Eurofins Discovery funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Eurofins Discovery M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Eurofins Discovery
What does Eurofins Discovery do?
Eurofins Discovery is a global contract research organization (CRO) providing drug discovery and safety pharmacology services to pharmaceutical and biotechnology companies. Its portfolio spans target identification through preclinical testing, including human bioassay development from diseased and normal human tissues, translational biology support, and safety assessment of drug candidates. The portfolio has been expanded through acquisitions such as DiscoveryBioMed (human tissue-based bioassays) and Calixar.
Is Eurofins Discovery a public or private company?
Eurofins Discovery is a private company. It is classified as corporate owned and is currently operating.
When was Eurofins Discovery founded?
Eurofins Discovery was founded in 1987. It employs 501 to 1,000 people.
Where is Eurofins Discovery based?
Eurofins Discovery is headquartered in St. Charles, United States, in the North America region.
How does Eurofins Discovery make money?
One revenue line is on record: contract Research Organization (CRO) Services.
Who are Eurofins Discovery's main competitors?
Sai Life Sciences is listed as an emerging player. Direct peers are Evotec, WuXi AppTec, Labcorp Drug Development (formerly Covance), Charles River Laboratories and Pharmaron. Broad incumbents are Thermo Fisher Scientific (PPD), IQVIA and Eurofins Scientific. Syneos Health is listed as a regional player.
Does Eurofins Discovery have an API?
No public API is recorded for Eurofins Discovery.
What industry is Eurofins Discovery in?
Eurofins Discovery's product category is Drug Discovery & Contract Research Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAC, Toxicology & Safety Assessment CROs (GLP). Its NAICS code is 541714 and its SIC code is 8731.